New immune cell therapy targets stubborn MS in early human trial
NCT ID NCT07178431
Summary
This early-stage trial is testing a new treatment called MB-CART 2019.1 for people with multiple sclerosis (MS) that continues to get worse despite standard medications. The study will first check if the treatment is safe and find the right dose, then see if it can stop all signs of disease activity for nearly a year. It involves collecting a patient's own immune cells, modifying them in a lab to potentially target MS, and then infusing them back.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Charité Universitätsmedizin Berlin
Berlin, 13353, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.